{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:07Z","timestamp":1793213407165,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04234-7","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:18:59Z","timestamp":1770304739000},"page":"3473-3487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of trilaciclib to prevent chemotherapy-induced myelosuppression in advanced solid tumors: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Muhammad","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. N. U.","family":"Deeksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-6221","authenticated-orcid":false,"given":"Ahsun Rizwan","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha Zartash","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Panhwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafaq","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bismah","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina Yousaf","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osaf Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqeeb Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niluka","family":"Weerakoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"4234_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1157251","volume":"14","author":"J Qiu","year":"2023","unstructured":"Qiu J, Sheng D, Lin F, Jiang P, Shi N. The efficacy and safety of trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1157251. https:\/\/doi.org\/10.3389\/fphar.2023.1157251.","journal-title":"Front Pharmacol"},{"issue":"8","key":"4234_CR2","doi-asserted-by":"publisher","first-page":"10020","DOI":"10.1002\/cam4.5655","volume":"12","author":"L Hart","year":"2023","unstructured":"Hart L, Ogbonnaya A, Boykin K, Deyoung K, Bailey R, Heritage T, et al. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: a retrospective study from community oncology practices. Cancer Med. 2023;12(8):10020\u201330. https:\/\/doi.org\/10.1002\/cam4.5655.","journal-title":"Cancer Med"},{"issue":"4","key":"4234_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ijc.29052","volume":"136","author":"R Cui","year":"2015","unstructured":"Cui R, Chu L, Liu Z, Xiao Y, Zhu X, Chen Y, et al. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials. Int J Cancer. 2015;136(4):936\u201344. https:\/\/doi.org\/10.1002\/ijc.29052.","journal-title":"Int J Cancer"},{"issue":"8","key":"4234_CR4","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1007\/s12325-020-01376-1","volume":"37","author":"RS Epstein","year":"2020","unstructured":"Epstein RS, Aapro MS, Basu Roy UK, Salimi T, Krenitsky J, Leone-Perkins ML, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. Adv Ther. 2020;37(8):3606\u201318. https:\/\/doi.org\/10.1007\/s12325-020-01376-1.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"4234_CR5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.3747\/co.v15i0.393","volume":"15","author":"BL Melosky","year":"2008","unstructured":"Melosky BL. Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol. 2008;15(Suppl 1):S10\u20135. https:\/\/doi.org\/10.3747\/co.v15i0.393.","journal-title":"Curr Oncol"},{"issue":"9674","key":"4234_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","volume":"373","author":"J Bohlius","year":"2009","unstructured":"Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(09)60502-X.","journal-title":"Lancet"},{"key":"4234_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103193","volume":"157","author":"P Lapidari","year":"2021","unstructured":"Lapidari P, Vaz-Luis I, Di Meglio A. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review. Crit Rev Oncol Hematol. 2021;157:103193. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103193.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"4234_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1055\/s-0044-1785574","volume":"45","author":"M Kapoor","year":"2024","unstructured":"Kapoor M, Sehrawat A, Sundriyal D. Trilaciclib: a novel approach to mitigate chemotherapy-induced myelosuppression in cancer treatment. Indian J Med Paediatr Oncol. 2024;45(4):320\u20132. https:\/\/doi.org\/10.1055\/s-0044-1785574.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"33","key":"4234_CR9","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.2217\/fon-2022-0364","volume":"18","author":"S Goel","year":"2022","unstructured":"Goel S, Tan AR, Rugo HS, Aftimos P, Andri\u0107 Z, Beelen A, et al. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: Phase III PRESERVE 2. Future Oncol. 2022;18(33):3701\u201311. https:\/\/doi.org\/10.2217\/fon-2022-0364.","journal-title":"Future Oncol"},{"issue":"10","key":"4234_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, et al. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol. 2019;30(10):1613\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdz158.","journal-title":"Ann Oncol"},{"key":"4234_CR11","doi-asserted-by":"publisher","unstructured":"Abraham I, Goyal A, Deniz B, Moran D, Chioda M, MacDonald KM, et al. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States. J Manag Care Spec Pharm. 2022;28(4):435\u201348. https:\/\/doi.org\/10.18553\/jmcp.2022.21315","DOI":"10.18553\/jmcp.2022.21315"},{"issue":"2","key":"4234_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams. Campbell Syst Rev. 2022;18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Rev"},{"key":"4234_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4234_CR14","unstructured":"Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 20 Sept 2025"},{"issue":"11","key":"4234_CR15","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30511-3","volume":"20","author":"AR Tan","year":"2019","unstructured":"Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019;20(11):1587\u2013601. https:\/\/doi.org\/10.1016\/S1470-2045(19)30511-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4234_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae116","volume":"9","author":"HJ Lenz","year":"2025","unstructured":"Lenz HJ, Liu T, Chen EY, Horv\u00e1th Z, Bondarenko I, Danielewicz I, et al. Trilaciclib prior to FOLFOXIRI\/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 preserve 1 trial. JNCI Cancer Spectr. 2025;9(1):pkae116. https:\/\/doi.org\/10.1093\/jncics\/pkae116.","journal-title":"JNCI Cancer Spectr"},{"issue":"10 Suppl","key":"4234_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.07.726","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Shi H. A phase II, randomized trial of trilaciclib plus chemotherapy and tislelizumab as first-line treatment for advanced squamous NSCLC. J Thorac Oncol. 2024;19(10 Suppl):S396. https:\/\/doi.org\/10.1016\/j.jtho.2024.07.726.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4234_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000847","volume":"8","author":"AY Lai","year":"2020","unstructured":"Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, et al. CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020;8(2):e000847. https:\/\/doi.org\/10.1136\/jitc-2020-000847.","journal-title":"J Immunother Cancer"},{"key":"4234_CR19","unstructured":"Targeted Oncology. Clinical trial evidence for the myeloprotective benefit of trilaciclib for chemotherapy-induced myelosuppression. 2022. Available from: https:\/\/www.targetedonc.com\/view\/clinical-trial-evidence-for-the-myeloprotective-benefit-of-trilaciclib-for-chemotherapy-induced-myelosuppression. Accessed 20 Sept 2025"},{"issue":"9","key":"4234_CR20","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1007\/s00520-024-08828-1","volume":"32","author":"J Elijah","year":"2024","unstructured":"Elijah J, Jain P, Holdsworth A, Baron J, Przespolewski E, Wang K, et al. Trilaciclib use in extensive-stage small cell lung cancer: are clinical benefits seen in the real-world setting? Support Care Cancer. 2024;32(9):4145\u201354. https:\/\/doi.org\/10.1007\/s00520-024-08828-1.","journal-title":"Support Care Cancer"},{"issue":"1","key":"4234_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01529-4","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart LL, Ferrarotto R, Andric ZG, Beck JT, Subramanian J, Radosavljevic DZ, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350\u201365. https:\/\/doi.org\/10.1007\/s12325-020-01529-4.","journal-title":"Adv Ther"},{"key":"4234_CR22","unstructured":"OncLive. Myelopreservation possible with CDK4\/6 inhibitor trilaciclib in TNBC. 2025. Available from: https:\/\/www.onclive.com\/view\/myelopreservation-possible-with-cdk46-inhibitor-trilaciclib-in-tnbc. Accessed 20 Sept 2025"},{"issue":"17","key":"4234_CR23","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1002\/cam4.4152","volume":"10","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Anderson I, Medgyasszay B, Garc\u00eda-Campelo MR, Edenfield W, Feinstein TM, et al. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials. Cancer Med. 2021;10(17):5748\u201356. https:\/\/doi.org\/10.1002\/cam4.4152.","journal-title":"Cancer Med"},{"issue":"4","key":"4234_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-21-2437","volume":"28","author":"AR Tan","year":"2022","unstructured":"Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, et al. Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study. Clin Cancer Res. 2022;28(4):629\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2437.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4234_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-021-01508-9","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Trilaciclib: first approval. Drugs. 2021;81(7):867\u201374. https:\/\/doi.org\/10.1007\/s40265-021-01508-9.","journal-title":"Drugs"},{"issue":"10","key":"4234_CR26","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.33385","volume":"148","author":"D Daniel","year":"2021","unstructured":"Daniel D, Kuchava V, Bondarenko I, Ivashchuk O, Reddy S, Jaal J, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2021;148(10):2557\u201370. https:\/\/doi.org\/10.1002\/ijc.33385.","journal-title":"Int J Cancer"},{"issue":"21","key":"4234_CR27","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2217\/fon-2024-0242","volume":"20","author":"J Crawford","year":"2024","unstructured":"Crawford J, Herndon D, Gmitter K, Weiss J. The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncol. 2024;20(21):1515\u201330. https:\/\/doi.org\/10.2217\/fon-2024-0242.","journal-title":"Future Oncol"},{"issue":"10","key":"4234_CR28","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s12325-023-02578-y","volume":"40","author":"J Goldschmidt","year":"2023","unstructured":"Goldschmidt J, Hart L, Scott J, Boykin K, Bailey R, Heritage T, et al. Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy. Adv Ther. 2023;40(10):4189\u2013215. https:\/\/doi.org\/10.1007\/s12325-023-02578-y.","journal-title":"Adv Ther"},{"key":"4234_CR29","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/CMAR.S319312","volume":"13","author":"M Hussein","year":"2021","unstructured":"Hussein M, Maglakelidze M, Richards DA, Sabatini M, Gersten TA, Lerro K, et al. Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res. 2021;13:6207\u201318. https:\/\/doi.org\/10.2147\/CMAR.S319312.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"4234_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3892\/ijmm.2025.6204","volume":"56","author":"F He","year":"2025","unstructured":"He F, Zhang Q, Chen Y, Ge S, Xie Y, Sun R, et al. The regulatory role of CDK4\/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy. Int J Mol Med. 2025;56(2):123. https:\/\/doi.org\/10.3892\/ijmm.2025.6204.","journal-title":"Int J Mol Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04234-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:08Z","timestamp":1784975348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04234-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4234"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04234-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no relationships that could be construed as a conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}